Sotalol
For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.
Active substance: Sotalol
Examples of brand names: Sotalex [DE]
ATC code: C07AA07
Main use (for orientation): Arrhythmias
Documented research summary
In a rhesus-monkey experiment, the heart-rate reduction after sotalol was attenuated during repeated intravenous Δ9-THC exposure. This is a direct preclinical pharmacodynamic finding, not clinical interaction evidence or assurance of safety.
Uncertainties and limitations
Only the accessible abstract assessed; no reliable prediction for usual routes, exposures, CBD or other cannabinoids. Do not independently change prescribed medicines on the basis of this research dataset.
Structured assessment
Category: Direct pair finding
Cannabinoid scope: Δ9-THC: one direct preclinical finding. No corresponding evidence for CBD or the other cannabinoids in the register.
Evidence status: Preclinical evidence: direct animal-experiment finding; abstract assessed.
Mechanism / drug context: Direct preclinical pharmacodynamic investigation: sotalol-induced heart-rate reduction was attenuated in rhesus monkeys after repeated intravenous Δ9-THC.
Type of supporting material: Experiment in conscious rhesus monkeys; additional older rabbit-eye experiment as limited context.
Clinical interpretation: Clinical significance in humans, QT prolongation and arrhythmia risk remain unresolved.
Context: Chronically catheterised conscious rhesus monkeys; repeated experimental Δ9-THC over three weeks. Not a human combination experiment.
Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.
Source role [RLABEL_D0198]: Original product information: drug context, not evidence for a cannabinoid–drug pair
Statement supported: Sotalol: predominantly eliminated unchanged by the kidneys, no relevant CYP metabolism; beta blockade, bradycardia and QT risks as drug context.
Source role [RMED6257883]: Direct preclinical pair evidence
Statement supported: Rhesus monkeys: attenuated heart-rate reduction after sotalol following repeated intravenous Δ9-THC.
Source: The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. [RMED6257883]
Source role [BMED1356]: Preclinical context; identity/methods incomplete
Statement supported: Eye experiment: sotalol antagonised the THC-related intraocular-pressure effect; PubMed indexes rabbits. THC isomer and full methods not unambiguous from the abstract.
Source: Interaction of adrenergic antagonists with prostaglandin E2 and tetrahydrocannabinol in the eye. [BMED1356]
Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.
Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Only the accessible abstract assessed; no reliable prediction for usual routes, exposures, CBD or other cannabinoids.
Separately recorded findings
1 separately recorded finding. Each statement applies to its documented study context.
THC – laboratory and animal studies
Finding ID: V6_D0198_1
Type of result: Finding within the documented study context
Observation: Sotalol-induced heart-rate reduction was attenuated in the rhesus-monkey model investigated.
Mechanism: Pharmacodynamic: altered autonomic response to beta blockade after repeated Δ9-THC exposure.
Study type: Rhesus-monkey experiment; accessible abstract assessed
Context studied: Conscious chronically catheterised rhesus monkeys, repeated intravenous Δ9-THC over three weeks; not a human combination study.
Clinical interpretation: Clinical significance in humans unclear; no safety, QT or dosage judgement.
Limitations and uncertainties: Full text not reread; sample size and complete methods unavailable from the abstract. Do not extrapolate to CBD, other cannabinoids or everyday administration forms.
Original sources for this finding: The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. [RMED6257883]
References and access status
[RLABEL_D0198] SOTALOL (SOTALOL HYDROCHLORIDE) TABLET SOTALOL HYDROCHLORIDE AF (SOTALOL HYDROCHLORIDE TABLES AF) TABLET SOTALOL HYDROCHLORIDE AF (SOTALOL HYDROCHLORIDE TABLETS AF) TABLET [UNICHEM PHARMACEUTICALS (USA), INC.]
Original source / bibliographic reference
Authors: Regulatory product information; respective marketing authorisation holder
Year: 2026
Source type: Product information / SmPC / US Prescribing Information
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
[RMED6257883] The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys.
Original source / bibliographic reference
Authors: Fredericks AB, Benowitz NL, Savanapridi CY.
Year: 1981
Source type: Original publication; see finding for study type
DOI: 10.1016/s0022-3565(25)32409-2
PMID: 6257883
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
[BMED1356] Interaction of adrenergic antagonists with prostaglandin E2 and tetrahydrocannabinol in the eye.
Original source / bibliographic reference
Authors: Green K, Kim K.
Year: 1976
Source type: Publication; title and abstract reviewed
PMID: 1356
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.
Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility
Sotalol and cannabinoids: documented findings, evidence, sources and data gaps. Research information for discussion with your doctor or pharmacist.